Human facilitative glucose transport protein GLUT8
AssigneeSt. Vincent's Institute of Medical Research
InventorsSuzanne Dawn Rogers, James Donovan Best
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel glucose transporter protein isolated from a breast cancer cell line, and to the gene encoding the protein. Detection of expression of the protein is useful as a diagnostic and staging marker in cancer. Control of expression of the protein is useful in the therapy of cancer. Furthermore, up-regulation of the protein is useful to overcome insulin resistance in non-insulin dependent diabetes mellitus.
Claims44
An isolated and purified nucleic acid molecule encoding a facilitative glucose transporter protein (GLUT8).
An isolated and purified nucleic acid molecule which hybridizes under stringent conditions to the sequence set out in SEQ ID NO:
- 4 or SEQ ID NO:
- 30.
A facilitative glucose transporter protein (GLUT8).
A method for diagnosing a malignant condition, comprising the steps of:
- (a) detecting expression or activity of GLUT8 in a tissue or cell;
- (b) correlating the expression or activity of GLUT8 with a malignant condition;
- and
- (c) diagnosing the malignant condition.
The method of monitoring of efficacy of treatment of a malignant condition, comprising the step of detecting activity or expression of GLUT8 in a tissue or cell.
A method of selecting a method of treatment of a malignant condition, comprising the step of measuring the ability of a proposed therapeutic agent to inhibit activity or expression of GLUT8 in a tissue or cell.
An antibody directed against GLUT8, or a functional fragment thereof.
A method of treating non-insulin dependent diabetes mellitus, comprising the step of upregulating expression of GLUT8 in a tissue or cell.
A method of detecting a mutation in the GLUT8 gene or regulatory sequence of a patient comprising the step of analyzing the gene or regulatory sequence for a nucleic acid change compared to that set out in SEQ ID NO:
- 3 or 4.
A method of screening putative agents for treatment of cancer, comprising the step of measuring the ability of the agents to inhibit the activity of GLUT8 in vitro or in vivo.
A method of screening putative agents for treatment of diabetes and/or insulin-resistance syndrome comprising the step of measuring the ability of the agents to upregulate or enhance the activity of GLUT8 in vitro or in vivo.
Dependencies are inferred from the claim text.